Peptomyc

4 articles about Peptomyc

• PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

  5/6/2021

  Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology and the Catalan Institute of Research and Advanced Studies in Barcelona, reported that on Tuesday 4th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d'Hebron in Barcelona.

• Peptomyc’s Omomyc-based therapy, OMO-103, has obtained approval for first-in-human phase I/II trial to assess the efficacy and safety of a novel Myc inhibitor

  3/18/2021

  Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L . has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound

• Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board

  1/6/2021

  Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics targeting the Myc oncoprotein for cancer treatment, announces today that has appointed veteran pharma and biotech executive Giacomo Di Nepi as Chairman of the Board . Mr. Di Nepi has accumulated nearly 40 years of global experience in the Healthcare sector . His career started with 16 years at McKinsey & Company, where he was a Partne

• Peptomyc's Innovation Targeting Cancer Wins Startup Slam Competition At BIO-Europe Spring Barcelona

  3/22/2017